Skip to main content

Buy Biocon, target Rs 823

We expect company to grow at a CAGR of around 29 percent over next two years which should also improve better profit margins going ahead.

  

Biocon has reported a growth of 21.2 percent in its consolidated revenues at Rs 1,123 crore in Q1-FY19 as against Rs 927 crore in Q1-FY18.
Profit after tax for the company grew by 47 percent and stood at Rs 119 crore in Q1-FY19 against Rs 81 crore in Q1-FY18.
The top 10 brands in its India portfolio reported a strong double digit growth.
The key developments during the quarter were approval of Fulphila (Pegfilgrastim) Biosimilar co-developed by Biocon and Mylan for launch in US markets.
The company’s sterile Drug Product manufacturing facility in Bengaluru received EIR from US FDA and EUGMP certification
Syngene extended its collaboration with Baxter upto 2024 and strengthens its growing client base amongst others.
Going ahead, we continue to expect company to get benefits of first wave of Biosimilar commercialisation in the next two years which should drive higher revenues along with higher growth in formulation business on back of new launches and deeper penetration.
We expect company to grow at a CAGR of around 29 percent over next two years which should also improve better profit margins going ahead.
MORE WILL UPDATE SOON!!
Labels:

Comments

Post a Comment

Popular posts from this blog

Income Tax Deductions List FY 2018-19 | List of important Income Tax Exemptions for AY 2019-20

Budget 2018-19 & the Finance Bill 2018 have been tabled in Parliament. The  Income Tax Slab rates  have been kept unchanged by the Finance Minister for the Financial Year 2018-19  (Assessment Year 2019-2020) . Tax planning is an important part of a financial plan. Whether you are a salaried individual, a professional or a businessman, you can save taxes to certain extent through proper tax planning. The Indian Income Tax act allows for certain Tax Deductions / Tax Exemptions which can be claimed to save tax. You can subtract tax deductions from your Gross Income and your taxable income gets reduced to that extent. In this post, let us go through the  Income Tax Deductions List FY 2018-19 . I hope you find this list useful and helps in planning your taxes well in advance. Income Tax Deductions List FY 2018-19 / AY 2019-20  (Chapter VI-A deductions list) Section 80c The maximum tax exemption limit under Section 80C has been retained as Rs 1.5...
2 comments
Read more

Buy IndusInd Bank, target Rs 2248

We expect the bank to maintain its stable asset quality over FY19-20 due to overall improvement in the rating profile of its corporate book and declining risk weightings of its vehicle-finance book. For   IndusInd Bank, the strategic Bharat Finance deal would be synergistic in the medium term. Growth would be primarily driven through the focus on the retail portfolio, as management intends to re balance  the corporate- and retail-book ratio to 50:50 (from 60:40). Credit growth grew 29.4% y/y in Q1-FY19, driven by secular growth across all segments, led by corporate (up 30% y/y), vehicle and retail (both up 28% y/y). We expect 26% loan growth in the medium term. Asset quality improved with slippages easing to 1.26% of loan book (down 83bps y/y, 111bps q/q) and credit cost softened to 55bps. MORE WILL UPDATE SOON!!
Post a Comment
Read more

Accumulate ICICI Bank, target Rs 386

Traders can accumulate the stock in a range of Rs 360-364 for the upside target of Rs 386 levels and a stop loss below Rs 345. For more than six weeks, ICICI Bank has been trading in a broader range of Rs 340-365 and is maintaining well above its short and long-term moving averages. At the current juncture, the stock formed an inverted head and shoulder pattern on the daily interval chart. Additionally, the positive divergences on secondary indicators are pointing toward upward movement in prices. So, traders can accumulate the stock in a range of Rs 360-364 for the upside target of Rs 386 levels and a stop loss below Rs 345.  MORE WILL UPDATE SOON!!
1 comment
Read more